SVN-015
SVN-015 is a serotonin–dopamine reuptake inhibitor (SDRI) which is under development for the treatment of major depressive disorder (MDD) and substance-related disorders such as stimulant use disorder.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
SVN-015 is a serotonin–dopamine reuptake inhibitor (SDRI) which is under development for the treatment of major depressive disorder (MDD) and substance-related disorders such as stimulant use disorder. It produces antidepressant-like effects in rodents similarly to the selective serotonin reuptake inhibitor (SSRI) fluoxetine.
SVN-015 is being developed by Solvonis Therapeutics, whose chief scientific officer (CSO) is David Nutt, in collaboration with the National Institute on Drug Abuse (NIDA). As of August 2026, the drug is in the preclinical research stage of development for all indications. The chemical structure of SVN-015 does not yet appear to have been disclosed.
However, Solvonis Therapeutics has patented monoamine transporter modulators.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1372052093 under CC BY-SA 4.0; modifications have been made.